var data={"title":"Vitamin A: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vitamin A: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7155?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vitamin-a-drug-information\" class=\"drug drug_general\">see &quot;Vitamin A: Drug information&quot;</a> and <a href=\"topic.htm?path=vitamin-a-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vitamin A: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234440\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>A-25 [OTC];</li>\n      <li>AFirm 1X [OTC] [DSC];</li>\n      <li>AFirm 2X [OTC] [DSC];</li>\n      <li>AFirm 3X [OTC] [DSC];</li>\n      <li>Aquasol A;</li>\n      <li>Gordons-Vite A [OTC];</li>\n      <li>Vitamin A Fish [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062927\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Nutritional Supplement</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vitamin, Fat Soluble</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12675815\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adequate Intake (AI):</b> Presented as retinol activity equivalent (RAE): 400 mcg/day (IOM 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lung disease, prevention in ELBW</b>: IM: 5,000 units/dose 3 times weekly (ie, Monday, Wednesday, and Friday) initiated within the first 96 hours of life and continued for 4 weeks; dosing based on a randomized controlled trial including 807 neonates (treatment group: n=405; mean GA: 26.8 weeks; mean birth weight: 770 g; range: 400 to 1,000 g) which showed a slight decreased risk for the development of chronic lung disease in treated patients (Tyson 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062922\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=vitamin-a-drug-information\" class=\"drug drug_general\">see &quot;Vitamin A: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Adequate Intake (AI)</b>: Presented as retinol activity equivalent (RAE) (IOM 2000):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 6 months: 400 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">6 to 12 months: 500 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended Daily Allowance (RDA):</b> Presented as retinol activity equivalent (RAE) (IOM 2000):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 3 years: 300 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4 to 8 years: 400 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">9 to 13 years: 600 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;13 years: Female: 700 mcg/day; Male: 900 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis supplementation:</b> <b>Note:</b> Typically administered as part of a fixed dosage product with other fat-soluble vitamins (eg, ADEK); however, some patients may require higher doses based on condition (CF liver disease [Debray 2011]); doses presented are in addition to usual RDA for age.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: Oral: 1,500 units/day (Borowitz 2002; Borowitz 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 3 years: Oral: 5,000 units/day (Borowitz 2002; Lahiri 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 8 years: Oral: 5,000 to 10,000 units/day (Borowitz 2002; Lahiri 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;9 years and Adolescents: Oral: 10,000 units/day (Borowitz 2002); some data suggest that dose should be individualized based on patient serum concentrations. Based on current US recommendations, some available multivitamin products may be excessive based on patient's needs, particularly in preadolescent patients (Bonifant 2014; Brei 2013; Graham-Maar 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malabsorption (eg, cholestasis, biliary atresia); supplementation:</b> Limited data available: Children and Adolescents: <b>Note:</b> Specific dose should be based on serum markers and clinical condition; dose should be individualized: Oral: 5,000 to 15,000 units/day of water miscible product (eg, Aquasol A); begin at low end of the range for younger patients (Kelly 2007; Kliegman 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Measles infection, supplementation</b>: Limited data available (WHO 2004; WHO 2010):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;6 months: Oral: 50,000 units daily for 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 6 to 11 months: Oral: 100,000 units daily for 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;12 months and Children &le;5 years: Oral: 200,000 units daily for 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note</b>: If severe malnutrition or ophthalmologic evidence of vitamin A deficiency is present, repeat a single dose 2 to 4 weeks after the second dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin A deficiency; prevention for geographical at-risk populations: Note:</b> Supplementation recommended in areas where vitamin A deficiency is a public health problem, including local prevalence of nightblindness &ge;1% in ages 24 to 59 months or prevalence of serum retinol &le;0.7 mmol/L is &ge;20% in ages 6 to 59 months (WHO 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;6 months: Oral: 100,000 units once</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;5 years: Oral: 200,000 units; administer as a single dose every 4 to 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin A deficiency, treatment: Note:</b> After completion of an IM course to correct deficiency, patient should continue on an oral supplementation for 2 months with a multivitamin preparation that contains: Infants and children &lt;8 years: 5,000 to 10,000 units/day; and children &ge;8 years and Adolescents: 10,000 to 20,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: IM: 7,500 to 15,000 units once daily for 10 days followed by oral supplementation</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 8 years: IM: 17,500 to 35,000 units once daily for 10 days followed by oral supplementation</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;8 years and Adolescents: IM: 100,000 units once daily for 3 days; then 50,000 units once daily for 14 days followed by oral supplementation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Xerophthalmia: </b>Limited data available (WHO 1997; WHO 2010):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;6 months: Oral: 50,000 units administered as a single dose; repeat the next day and again after at least 2 weeks for a total of 3 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 6 to 12 months: Oral: 100,000 units administered as a single dose; repeat the next day and again after at least 2 weeks for a total of 3 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: Oral: 200,000 units administered as a single dose; repeat the next day and again after at least 2 weeks for a total of 3 doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Deficiency:</b> IM: <b>Note:</b> IM route is indicated when oral administration is not feasible or when absorption is insufficient (malabsorption syndrome): 100,000 units/day for 3 days, followed by 50,000 units/day for 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Follow-up therapy with an oral therapeutic multivitamin (containing additional vitamin A) is recommended: Oral: 10,000 to 20,000 units/day for 2 months</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234422\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">A-25: 25,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vitamin A Fish: 7500 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">A-25: 25,000 units [dye free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 8000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AFirm 1X: 0.15% (30 g [DSC]) [fragrance free; contains benzyl alcohol, cetyl alcohol, disodium edta, methylparaben, peg-10 soya sterol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AFirm 2X: 0.3% (30 g [DSC]) [fragrance free; contains benzyl alcohol, cetyl alcohol, disodium edta, methylparaben, peg-10 soya sterol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AFirm 3X: 0.6% (30 g [DSC]) [fragrance free; contains benzyl alcohol, cetyl alcohol, disodium edta, methylparaben, peg-10 soya sterol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gordons-Vite A: 100,000 units/g (75 g, 120 g, 480 g, 2400 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lotion, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gordons-Vite A: 100,000 units (120 mL, 4000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aquasol A: 50,000 units/mL (2 mL) [contains chlorobutanol (chlorobutol)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10,000 units, 15,000 units, Vitamin A 10000 units and beta carotene 1000 units</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234408\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062930\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with food or milk; for infants and children &lt;24 months of age, capsules may be cut open and contents squeezed into the mouth </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: <b>For IM use only</b>; for neonatal patients, a 0.3 mL syringe and 29-gauge needle should be used for IM dose administration </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234435\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Injection: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. The following stability information has also been reported for Aquasol A injection: May be stored at room temperature for up to 4 weeks (Cohen 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062929\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of vitamin A deficiency (injection: FDA approved in all ages; oral: FDA approved in adults); has also been used for prevention of vitamin A deficiency, supplementation in infants and children &le;5 years with measles, and prevention of chronic lung disease in premature neonates </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234464\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aquasol may be confused with Anusol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234461\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity: Anaphylactic shock (following IV administration), hypersensitivity reaction (rare)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234428\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to vitamin A or any component of the formulation; hypervitaminosis A; pregnancy (dose exceeding RDA); intravenous administration of Aquasol A</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234412\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parenteral vitamin A: In low birth weight infants, polysorbates have been associated with thrombocytopenia, renal dysfunction, hepatomegaly, cholestasis, ascites, hypotension, and metabolic acidosis (E-Ferol syndrome).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Evaluate other sources of vitamin A while receiving this product; patients receiving &gt;25,000 units/day should be closely monitored for toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300220\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234417\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12883&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bexarotene (Topical): Vitamin A may enhance the adverse/toxic effect of Bexarotene (Topical).  Management: Limit doses of vitamin A to 5,000 units per day if combined with topical bexarotene.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat.  Similar precautions do not apply to parenterally administered fat soluble vitamins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Retinoic Acid Derivatives: Vitamin A may enhance the adverse/toxic effect of Retinoic Acid Derivatives. <b> Exceptions: </b>Adapalene; Alitretinoin (Topical); Bexarotene (Topical); Tretinoin (Topical).<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14315239\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Excessive ethanol intake depletes the liver of vitamin A and may enhance vitamin A toxicity (IOM 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234419\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234431\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. In humans, the critical period of exposure is the first trimester of pregnancy. Excess vitamin A during pregnancy may cause craniofacial malformations, as well as CNS, heart, and thymus abnormalities. Maternal vitamin A deficiency also causes adverse effects in the fetus, and vitamin A requirements are increased in pregnant women (IOM 2000). The manufacturer notes that the safety of doses &gt;6,000 units/day in pregnant women has not been established and doses greater than the RDA are contraindicated in pregnant women or those who may become pregnant. High doses are used in some areas of the world for supplementation where deficiency is a public health problem (eg, to prevent night blindness); however, single doses &gt;25,000 units should be avoided within 60 days of conception. High-dose supplementation is otherwise not recommended as part of routine antenatal care (WHO 2011c).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51083803\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum retinol (baseline, 1 to 2 months after start of therapy [eg, CF infants, preschoolers], and annually at minimum [eg, chronic conditions]) (Borowitz 2002; Borowitz 2009; Debray 2011; Kelly 2007; Lahiri 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234411\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Vitamin A is a fat soluble vitamin needed for visual adaptation to darkness, maintenance of epithelial cells, immune function and embryonic development.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234427\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Vitamin A in dosages <b>not</b> exceeding physiologic replacement is well absorbed in the small intestine after oral administration; water miscible preparations are absorbed more rapidly than oil preparations; large oral doses, conditions of fat malabsorption, low protein intake, or hepatic or pancreatic disease reduces oral absorption </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Large amounts concentrate for storage in the liver</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Converted in the small intestine to retinol and further metabolized in the liver; conjugated with glucuronide; undergoes enterohepatic recirculation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces; urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062934\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">1 USP vitamin A unit = 0.3 mcg of all-<i>trans</i> isomer of retinol; 1 RAE (retinol activity equivalent) = 1 mcg of all-<i>trans</i>-retinol = 12 mcg of dietary beta-carotene (IOM 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324099\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Vitamin A Fish Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7500 unit (100): $2.55</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Vitamin A Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8000 unit (100): $2.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 unit (100): $2.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Gordons-Vite A External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100000 units/g (120 g): $15.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Gordons-Vite A External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100000 unit (120 mL): $7.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aquasol A Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50000 units/mL (2 mL): $120.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Vitamin A-Beta Carotene Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000-1000 unit (90): $8.49</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539954\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>A Grin (MX);</li>\n      <li>A313 (FR);</li>\n      <li>Acon (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Arovit (AE, BE, BH, BR, CO, CY, EC, EG, IL, IQ, IR, IT, JO, KW, LB, LY, OM, PE, QA, SA, SE, SY, YE);</li>\n      <li>Avibon (FR);</li>\n      <li>Avitan (GR);</li>\n      <li>Avitina (IT);</li>\n      <li>Avitol (AT);</li>\n      <li>Davitamon A (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ro-A-Vit (GH, KE, TZ, UG, ZM);</li>\n      <li>Vitamin A (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aquasol A Parenteral (water-miscible vitamin A palmitate) [prescribing information]. Lake Forest, IL: Hospira; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonifant CM, Shevill E, Chang AB. Vitamin A supplementation for cystic fibrosis. <i>Cochrane Database Syst Rev</i>. 2014;(5):CD006751.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/24823814/pubmed\" target=\"_blank\" id=\"24823814\">24823814</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. <i>J Pediatr Gastroenterol Nutr</i>. 2002;35(3):246-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/12352509/pubmed\" target=\"_blank\" id=\"12352509\">12352509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borowitz D, Robinson KA, Rosenfeld M, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. <i>J Pediatr</i>. 2009;155(6 Suppl):S73-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/19914445/pubmed\" target=\"_blank\" id=\"19914445\">19914445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brei C, Simon A, Krawinkel MB, Naehrlich L. Individualized vitamin A supplementation for patients with cystic fibrosis. <i>Clin Nutr</i>. 2013;32(5):805-810.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/23395254/pubmed\" target=\"_blank\" id=\"23395254\">23395254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al. Room-temperature storage of medications labeled for refrigeration. <i>Am J Health-Syst Pharm</i>. 2007;64(16):1711-1715.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. <i>J Cyst Fibros</i>. 2011;10 Suppl 2:S29-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/21658639/pubmed\" target=\"_blank\" id=\"21658639\">21658639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeMaeyer EM, &ldquo;The WHO Programme of Prevention and Control of Vitamin A Deficiency, Xerophthalmia, and Nutritional Blindness,&rdquo; <i>Nutr Health</i>, 1986, 4(2):105-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/3090484/pubmed\" target=\"_blank\" id=\"3090484\">3090484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graham-Maar RC, Schall JI, Stettler N, Zemel BS, Stallings VA. Elevated vitamin A intake and serum retinol in preadolescent children with cystic fibrosis. <i>Am J Clin Nutr</i>. 2006;84(1):174-182.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/16825693/pubmed\" target=\"_blank\" id=\"16825693\">16825693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hussey GD and Klein M, &ldquo;A Randomized, Controlled Trial of Vitamin A in Children With Severe Measles,&rdquo; <i>N Engl J Med</i>, 1990, 323(3):160-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/2194128/pubmed\" target=\"_blank\" id=\"2194128\">2194128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>, Washington, DC: National Academy Press, 2000.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly DA, Davenport M. Current management of biliary atresia. <i>Arch Dis Child</i>. 2007;92(12):1132-1135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/17878208/pubmed\" target=\"_blank\" id=\"17878208\">17878208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lahiri T, Hempstead SE, Brady C, et al. Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis. <i>Pediatrics</i>. 2016;137(4). pii: e20151784.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-a-pediatric-drug-information/abstract-text/27009033/pubmed\" target=\"_blank\" id=\"27009033\">27009033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tyson JE, Wright LL, Oh W, et al, &quot;Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants. National Institute of Child Health and Human Development Neonatal Research Network,&quot; <i>N Engl J Med</i>, 1999, 340(25):1962-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Treating Measles in Children. 2004. Available at http://www.who.int/immunization_delivery/interventions/TreatingMeaslesENG300.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    WHO Guideline, &quot;Vitamin A Supplementation in Infants 6-59 Months of Age,&quot; Geneva: World Health Organization, 2011. Available at http://www.who.int/nutrition/publications/micronutrients/guidelines/vas_6to59_months/en/index.html </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    WHO Guideline, &quot;Vitamin A Supplementation in Postpartum Women,&quot; Geneva: World Health Organization, 2011b. Available at http://www.who.int/nutrition/publications/micronutrients/guidelines/vas_postpartum/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    WHO Guideline, &quot;Vitamin A Supplementation in Pregnant Women,&quot; Geneva: World Health Organization, 2011c. Available at http://www.who.int/nutrition/publications/micronutrients/guidelines/vas_pregnant/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      WHO Model Formulary for Children, 2010. Available at http://apps.who.int/medicinedocs/en/m/abstract/Js17151e/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    WHO/UNICEF/IVACG Task Force, Vitamin A Supplements. A Guide to Their Use in the Treatment and Prevention of Vitamin A Deficiency and Xerophthalmia, 2nd ed. Geneva: World Health Organization, 1997. Available at http://www.who.int/nutrition/publications/micronutrients/vitamin_a_deficiency/9241545062/en/</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12883 Version 90.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F234440\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062927\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12675815\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062922\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F234422\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F234408\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062930\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F234435\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062929\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F234464\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F234461\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F234428\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F234412\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300220\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F234417\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F14315239\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F234419\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F234431\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F51083803\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F234411\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F234427\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1062934\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324099\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539954\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12883|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vitamin-a-drug-information\" class=\"drug drug_general\">Vitamin A: Drug information</a></li><li><a href=\"topic.htm?path=vitamin-a-patient-drug-information\" class=\"drug drug_patient\">Vitamin A: Patient drug information</a></li></ul></div></div>","javascript":null}